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The diagnosis of prostate cancer in men in US continues to be a burden due to painfulness, non-specificity,
and false positives of current methods. The usage of radiolabeled peptides as targeting vectors that
selectively target cancer biomarkers or cell-surface receptors has been an active field and investigated for
decades. However, the radiotracer equipped with more than one type of peptide targeting motif for two
distinct biomarkers that are co-expressed in human tumors has not been exploited thoroughly. This
dissertation is focused on the so-called bivalent ligand, a radiotracer that has two types of targeting motifs
for two different biomarkers. Several bivalent ligands composed of different targeting vectors are discussed.
The first bivalent ligand, [DUPA-6-Ahx-K-5-Ava-BBN(7-14)NH2], for targeting both GRPR (gastrin releasing
peptide receptor) and PSMA (prostate specific membrane antigen) was synthesized, and conjugated with
NODAGA ([2-(4,7-biscarboxymethyl)-1,4,7-(triazonan-1-yl)pentanedioic acid]). The NODAGA conjugate,
[DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], was radiolabeled with Cu-64, and evaluated biologically.
The study demonstrated the capability of the bivalent ligand to target both biomarkers. 
The second bivalent ligand was [RGD-Glu-6-Ahx-RM2], which has the capability of targeting both GRPR
and alpha-v beta-3 integrin. [RGD-Glu-6-Ahx-RM2] was conjugated with NOTA (1,4,7-triazacyclononane-
1,4,7-triacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), respectively.
The NOTA conjugate, [RGD-Glu-(NO2A)-6-Ahx-RM2], and DOTA conjugate, [RGD-Glu-(DO3A)-6-Ahx-
RM2], were characterized, radiolabeled with Cu-64/Ga-67, and investigated biologically. The study
indicated the potential of the ligand for targeting prostate cancer in vivo. However, further optimizations of
the ligands are warranted for superior pharmacokinetics in vivo.
